NCT06682572Phase 2Active not recruiting

A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

Study sponsor: Verastem, Inc. · VSTM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-12Estimated
Enrollment · participants16Actual
Source updated2025-12-17Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 15 participants (planned). After: 16 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source